“It's only fatness, it doesn't kill”: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda
Background Dolutegravir (DTG)-based regimens have been recommended by the WHO as
the preferred first-line and second-line HIV treatment in all populations. Evidence suggests …
the preferred first-line and second-line HIV treatment in all populations. Evidence suggests …
The impact of shifts in PEPFAR funding policy on HIV services in Eastern Uganda (2015–21)
H Zakumumpa, L Paina, E Ssegujja… - Health policy and …, 2024 - academic.oup.com
Although donor transitions from HIV programmes are increasingly common in low-and
middle-income countries, there are limited analyses of long-term impacts on HIV services …
middle-income countries, there are limited analyses of long-term impacts on HIV services …
Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study
Background The literature on dolutegravir (DTG)-based HIV treatment has focused on
assessing therapeutic efficacy particularly with regard to viral load suppression. However …
assessing therapeutic efficacy particularly with regard to viral load suppression. However …
Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda
H Zakumumpa, A Alinaitwe, M Kyomuhendo… - BMC Infectious …, 2024 - Springer
Introduction Long-acting injectable antiretroviral treatment (LAI-ART) has emerged as a
novel alternative to the burden of daily oral pills. The bi-monthly intramuscular injectable …
novel alternative to the burden of daily oral pills. The bi-monthly intramuscular injectable …
Effectiveness and Tolerability of Dual Therapy with Dolutegravir Plus Darunavir/cobicistat in Treatment-Experienced Patients with HIV: A 144-Week Follow-Up
SW Kim, HW Jang, HH Chang, Y Kim… - Infection & …, 2024 - pmc.ncbi.nlm.nih.gov
Background A dual regimen with dolutegravir plus cobicistat-boosted darunavir (DTG+
DRV/c) is a promising alternative for patients with human immunodeficiency virus (HIV) with …
DRV/c) is a promising alternative for patients with human immunodeficiency virus (HIV) with …
Perceptions of people living with human immunodeficiency virus regarding the use of a dolutegravir-based regimen, Limpopo Province
ZR Sibeko - 2023 - repository.nwu.ac.za
Background: Progress to manage HIV has been implemented over the years and
introduction of antiretroviral therapy (ART's) has been a great achievement. Dolutegravir …
introduction of antiretroviral therapy (ART's) has been a great achievement. Dolutegravir …
The effect of the HIV-antiretroviral Dolutegravir on glucose homeostasis in healthy mice and its implication on fetal toxicity
V Dontsova - 2022 - search.proquest.com
Dolutegravir (DTG)-containing antiretroviral therapy is a preferred regimen for all people
living with HIV. However, DTG use has been associated with weight gain and rare events of …
living with HIV. However, DTG use has been associated with weight gain and rare events of …
The effect of Dolutegravir on redox and vascular integrity
J Conradie - 2022 - scholar.sun.ac.za
Background: Of the estimated 7.2 million people living with HIV (PLWH) in South Africa,
more than 50% are on antiretroviral (ARV) medication. Dolutegravir (DTG), an integrase …
more than 50% are on antiretroviral (ARV) medication. Dolutegravir (DTG), an integrase …